Pathogenesis of graft-versus-host-disease

Overview of Graft-Versus-Host Disease with Emphasis on the Pathogenesis of Autologous Graft-Versus-Host Disease

GVHD: Graft-Versus-Host Disease; HSCT: Hematopoietic Stem Cell Transplantation; CsA: Cyclosporine; MHC: Major Histocompatibility Complex; CLIP: Class II Invariant Chain Peptide; IL-2: Interleukin-2; IL-4: Interleukin-4; IL-5: Interleukin-5; IL-10: Interleukin-10; IFN-γ:Interferon-γ; TNF-α: Tumor Necrosis Factor-α; TGF-β: Transforming Growth Factor-β; TCR: T-Cell Receptor; SEB: Staphylococcal En...

Graft Versus Host Disease

Commonly referred to as GVHD, graft-versus-host disease is a man-made condition that arises when patients are transplanted with donor tissue that is not identical to their own. Transplants from other individuals are called allogeneic (‘allo’ meaning ‘other’ and ‘geneic’ referring to ‘genes’). GVHD occurs after hematopoietic stem cell or bone marrow transplantation but is most commonly experienc...

Graft versus Host Disease

Definition Graft-versus-host disease (GVHD) is the most common complication of allogeneic hematopoietic stem cell transplantation (HSCT). In HSCT, the patient’s bone marrow is destroyed with chemotherapy and/or radiation and replaced by donor hematopoietic stem cells. In allogeneic HSCT the donor is usually a close family member or occasionally someone outside the family who has been found to b...

Graft-versus-host disease or graft-versus-host-like syndrome.

Acute graft versus host disease

Acute graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins with the preparative regimen. About 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute GVHD. The exact risk is...